Relevium Signs JV for E-Commerce AI With Blockchain Technology Integration, Proposes Initial Coin Offering
Momentum Public Relations
Press Release: 2018-01-11
Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) (the “Company” or “Relevium”), is pleased to announce the signing of a joint venture agreement (“JV”) with Quantomic LLC (the “Parties”) for Tagspire, a virtual retail and visual commerce platform.
Highlights
- Tagspire uses AI and Machine Learning to auto-tag products to retailers in photos and videos
- Product database of over 35 million and growing
- Tagspire is fully operational on iOS and Android
- JV consummated on a proposed Initial Coin Offering (ICO) or equity financing of USD 20MM+
- Relevium will integrate the platform to the blockchain as a network utility token
Note to reader: There are multiple hyperlinks in this news release. If the reader cannot see the hyperlinks, please consult http://releviumtechnologies.com/press-releases/ where a version of the release with hyperlinks is available.
Aurelio Useche, CEO of Relevium Technologies stated: “Initially announced on September 7, 2017, Relevium has been looking at how to integrate AI and machine learning in the e-commerce space.” Mr. Useche continued: “The team quickly found out that the biggest hurdle was to have enough data in order to gain insight on consumer behaviour. Tagspire solves this issue as all user data is generated in the Tagspire ecosystem and then pushed out to platforms such as Instagram, YouTube, Facebook, Twitter, Pinterest, etc. The team at Relevium believes that the Tagspire platform is a perfect candidate for blockchain integration as a network token and an ICO.”
Karim Hijazi, President and Founder of Quantomic LLC stated: “I created Tagspire when witnessing the rise of visual platforms like Pinterest, Instagram and Snapchat; where immense amounts of time and creativity were being spent producing content. However, effective monetization of that content was still nascent.”
Mr. Hijazi went on to state: “With Tagspire, the goal was to create a truly immersive, fun and social marketplace platform that would appeal not only to entrepreneurial consumers, but also to influencers and brands alike. I believe that user-generated content leveraged appropriately and effectively will be the next big disruptor in retail; not to mention the unparalleled intelligence that could be gleaned from it.”
What is Tagspire?
Tagspire is a virtual retail and visual commerce platform, the purpose of which is to deliver high fidelity marketing intelligence to brands, harvested from user-generated content. Presently, Tagspire can be used on iOS, Android and as a WebApp and browser extension. When images are captured and pushed to social media, users earn a commission on any sales made from items/objects that are tagged in their photos or videos.
Tagspire is a sales engine inside an Instagram-like environment capitalizing on discovery and the “impulse purchase” facilitated by a familiar face. Auto-tagging functionalities are currently being deployed and the artificial intelligence engine – using Google TensorFlow – can recognize over 35,000,000 retail products ranging from apparel to electronics and cosmetics. The Tagspire technology is in constant evolution and can already auto-generate tags on static images as well as in video clips. Tagspire currently connects to such retailers as: Best Buy, Avon, Target and American Eagle. A full list of currently connect retails can be found at tagspire.com/retailers.
To illustrate the power of the technology, click here to watch a short video illustrating the Tagspire mobile app. The technology identifies an Apple iPhone in a photo taken by the app, and then auto-tags the product in the image, linking it to the apple.com purchase page. Using the power of Google TensorFlowmachine learning, the Tagspire neural network has been trained to identify an “Apple iPhone Red Product” and then link it automatically, in this case, to the buy page on apple.com. The final post is embedded here(make sure to roll your mouse over, or tap the tag icon to see a preview of the buy page).
Tagspire is currently operational and is available in the Apple iTunes Store for iOS (click here), as well as for Android (click here) in the Google Play Store.
Initial Purpose and Principal Terms of Joint Venture
The Parties will combine resources to raise capital through either an ICO or initial token offering on an existing blockchain or through the capital markets (the “Offering”) for gross proceed of no less than USD$20 million. If the Offering is structured as an ICO, it is expected that it will be completed through a newly created entity (“NEWCO”) using the current best practices for coin and token offerings. If the Offering is structured as an equity or debt financing through traditional capital raising mechanisms (for example investment dealers), it will be completed through Relevium Technologies. Management of Relevium Technologies is working towards the structure of the Offering and will disclose terms as they become finalized.
A USD$8 Million portion of the proceeds of the Offering will be paid to Quantomic LLC allowing Relevium to secure a 51% ownership stake of NEWCO. The balance of no less than USD$12 Million, will be used to fund NEWCO and the continued development of the Tagspire platform and ecosystem, including blockchain integration, data set acquisitions, AI programming and training, server and software costs, marketing and human resources. It is anticipated that the initial management team of NEWCO will be comprised of the current management team from Quantomic LLC and complimented by human and intellectual capital from Relevium Technologies. Upon consummation of the JV, NEWCO will operate as a subsidiary to Relevium Technologies and the Board of NEWCO will be represented by both JV Parties.
The Parties also agree to cooperate and contribute the following:
(i) Relevium shall contribute all the costs, know-how and resources necessary to ensure a successful token offering or financing to fund the Offering, including preliminary due diligence of the IP, definition of the project, attributes of the proposed token, preparation of the white paper, legal and accounting fees, compliance, marketing and overall management of the financing of the JV.
(ii) Quantomic LLC shall contribute the intellectual assets, licenses, trademarks, patents, proprietary information, copyright and content necessary to demonstrate the current and prospective value of the IP.
While the Parties have agreed to use their commercially reasonable efforts to complete the Offering, there can be no guarantee that the Offering and JV will be completed as currently contemplated by the Parties or at all.
Right of First Refusal
Quantomic LLC acknowledges that Relevium will be incurring substantial costs to finalize the terms of the JV and the Offering. As partial consideration of the JV, Quantomic LLC agrees for a period of 60 days not to enter into any new negotiations or discussions with any third party in respect of the sale of all or any part of its shares, business or assets. However, Quantomic LLC may continue existing and ongoing discussions with third parties regarding the potential acquisition of its intellectual property. Prior to accepting any bona fide offer, Quantomic LLC must give notice to Relevium as the Company has a right of first refusal on any such offers.
Pursuant to regulatory guidelines, further financial details and related fees regarding the joint venture will be disclosed in connection with the closing of the transaction.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that is incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche, President and CEO
RELEVIUM TECHNOLOGIES INC.
Email: eierfino@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Edward Ierfino
Investor Relations
+1 (514) 562-1374
- Published in Relevium Technologies, Technology
Relevium Announces First Quarter Results with Revenues of 1.15 Million
Momentum Public Relations
Press Release: November 30, 2017
Relevium Technologies Inc. has released its unaudited financial results for the three-month period ended Sept. 30, 2017.
Financial Highlights
This is the first reporting period that consolidates the results of the acquisition of BioGanix Ltd. (“Bioganix”) (see Press Release issued on June 12, 2017) and illustrates:
- Consolidated revenues of $1.15 Million;
- Adjusted EBITDA* of $154,427 or 13{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} as a percentage of sales;
- Total Assets of $7.1 Million and Total Liabilities of $4.9 Million;
- 65 million shares outstanding.
Aurelio Useche, CEO of Relevium Technologies stated: “This new fiscal year beginning July 1, 2017 will be a transformational year for Relevium. The financial statements and Management Discussion and Analysis as filed on www.sedar.com consolidate the results of BGX E-Health LLC, the wholly-owned subsidiary in the US that operates the assets of BioGanix, the recently acquired B2C nutraceutical business. Mr. Useche added: “The first three months of post-acquisition is a resource and capital-intensive period for any company. The positive EBITDA results and growing revenues indicate to us that the transition of the business has been successful.”
Adjusted EBITDA* Reconciliation $ Net Loss (127,776) Interest on long term debt 107,617 Accreted interest 96,443 Acquistions and related costs 78,137 Adjusted EBITDA* 154,421 *= Adjusted EBITDA is a non-IFRS financial measurement
Non-Financial Highlights
- The Company successfully completed the first half of its active transition period for the acquisition of BioGanix with increased revenues as compared to the same period under the previous ownership
- Launched the first stage of a project to incorporate predictive AI technology for new product selection
- Secured an exclusive partnership with Salvania Nutrition and Biodevas for the launching in 2018 of a nutraceutical and phytoceuticals product line for companion pets.
Aurelio Useche, CEO of Relevium Technologies stated: “Over the second quarter of this new, fiscal year our focus has shifted from integration to organic growth through marketing optimization, new product launches, technology integration and the establishment of key exclusive partnerships to ensure strategic differentiation in our product offering and the build-up of equity for our brands.”
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
We seek Safe Harbor.
- Published in News Home, Relevium Technologies
Relevium & HempCo Sign Exclusive Product Agreement for PlanetHemp
Momentum Public Relations
Press Release: November 23, 2017
MONTREAL, QUEBEC–(Marketwired – Nov. 23, 2017) – Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) (the “Company” or “Relevium”), a publicly-traded corporation strategically focused on creating value through the acquisition and development of e-brands, online businesses and e-retail technologies in the Health and Wellness space, is pleased to announce the signing of an exclusive brand and product assignment with HempCo Canada (“HempCo”) for the Planet Hemp brand.
Highlights
- Exclusive Brand and Product Assignment for the PlanetHemp brand
- Relevium will market PlanetHemp products in the US and UK
- Exclusivity for online sales through Amazon, Walmart/Jet and others
- Cooperate in developing new formulations and applications
- Initial 2-year term
Aurelio Useche, CEO of Relevium Technologies stated: “Initially announced on May 10, 2017, this Agreement has been a long time in the making.” Mr. Useche continued: “This Exclusivity Agreement could not come at a better time as people are gearing up for the Holiday Season, and the Relevium Operations Team is gearing up to help people with their post-Holiday wellness plans. Relevium is looking forward to bringing quality PlanetHempproducts to the US and UK in 2018. We also look forward to developing new products with the team at HempCo, especially as the regulatory environment for certain hemp and CBD-infused products becomes more favorable.”
Purpose
Relevium and HempCo have signed an Exclusive Brand and Product Assignment (the “Exclusivity Agreement“). The Exclusivity Agreement confirms that Relevium and HempCo intend to cooperate in the business development, branding, marketing and e-retailing of PlanetHemp and all the Hempco products. This includes proteins, seed, oils, natural bars, pet products and CBD-infused products currently sold by HempCo on a B2B basis and on a B2C basis, through its brand PlanetHemp. The parties have agreed to create value through exclusive e-retailing rights of PlanetHemp in the USA and UK through Amazon and its Website, as well as possible brand extension to sell in Jet, Flipkart, Alibaba and other online retail platforms such as Walmart.com and Costco.com.
Exclusivity
Relevium will sell and introduce new products under the PlanetHemp brand for the United States (USA) and the United Kingdom (UK) as per the above list of e-retailing venues only and unless otherwise approved in writing by HempCo. Additionally, and with HempCo written permission, Relevium might introduce parallel e-commerce brands of the same products in the same territories; for the purposes of pursuing business in platforms that would complement the market strategy and spirit of cooperation in this Agreement.
New Product Lines
In the spirit of cooperation Relevium and HempCo will cooperate in the development of new products, formulations as well as new applications for the Nutrition, Nutraceutical, Fitness Nutrition and Skin-Care markets, to ensure an ongoing pipeline of new products entering the market. Relevium and HempCo respectively have the technical and marketing expertise to develop and brand the exclusive products.
Term of Exclusivity
The initial term of this Agreement shall continue in full force and effect for a period of two (2) years (the “Initial Term”). Provided Relevium has complied with all the terms and conditions and achieved the Minimum Annual Performance Requirements, this Agreement shall be automatically renewed at the end of the Initial Term or any Renewal Term, as the case may be, on the same terms and conditions as set forth herein, save and except the Minimum Annual Performance Requirements which shall be increased in accordance with the terms, for successive periods of three (3) year(s) (in each case a “Renewal Term”).
MINIMUM ANNUAL PERFORMANCE REQUIREMENTS | ||
Year | Annual Period | Dollar Amount (CAD) |
1 UK | January 1, 2018 to December 31, 2019 | $200,000 |
2 UK | January 1, 2019 to December 31, 2020 | $400,000 |
1 USA | January 1, 2018 to December 31, 2019 | $600,000 |
2 USA | January 1, 2019 to December 31, 2020 | $1,200,000 |
total | $2,400,000 |
Cooperation Conditions
The parties have executed a final Agreement and will begin the process in an expeditious manner in order not to miss the post-holiday season in 2018.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking information within the meaning of applicable securities legislation, which reflects the Company’s current expectations regarding future events. Forward-looking information is based on several assumptions and is subject to several risks and uncertainties, many of which are beyond the Company’s control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Readers should not place undue reliance on forward-looking statements and forward-looking information and are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake any obligation to update such forward-looking information, whether because of new information, future events or otherwise, except as expressly required by applicable law.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche, President and CEO
Website: www.releviumtechnologies.com
Relevium Technologies Inc.
Edward Ierfino
Investor Relations
(514) 562-1374
eierfino@releviumcorp.com
www.releviumtechnologies.com
- Published in Business, News Home, Relevium Technologies, Technology
Relevium Drives Top Line Growth for Q1
Momentum Public Relations
Press Release: November 6, 2017
MONTREAL, QUEBEC–(Marketwired – Nov. 6, 2017) – Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) (the “Company” or “Relevium”), a publicly traded corporation strategically focused on creating value through the acquisition and development of e-brands, online businesses and e-retail technologies in the Health and Wellness space, is pleased to announce top line growth for Q1 in anticipation of its interim filings.
What’s New Here?
- Revenues increased by 47{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} for the newly acquired BioGanix business in Q1, as compared to sales during the same period last year under the previous ownership.
- Number of units sold increased from 27,084 in 2016 to 42,003.
- Number of subscribers is now 225,000, a 60{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} increase and the number of SKUs is now 26 (32 by year end)
What Does This Mean?
In M&A, the first six months of integration tends to be the most critical period, as such:
- Revenue growth is a good indicator that the integration process is going well
- The increase in customer base and the introduction of new products reflect management’s investment in organic growth and brand equity
Why Should Investors Care?
- Management is executing as promised:
(1) Delivering on the first acquisition and
(2) Optimizing the acquired business - Investors can expect continued focus on brand equity and product line expansion
- Following the successful integration period, management is setting the stage for its next execution challenge
First Quarter Disclosure
The Company’s Fiscal Year 2018 started on July 1, 2017 and as such, shareholders can expect to see the full impact of the results from the Bioganix acquisition in Q1 of this new fiscal year, due at the end of this month.
The Company is expecting to hold a conference call for shareholders to discuss the results of Q1, as well as other business developments. The date and time of the conference call is to be announced on a separate press release.
About Relevium Technologies
Relevium is a TSXV listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking information within the meaning of applicable securities legislation, which reflects the Company’s current expectations regarding future events. Forward-looking information is based on several assumptions and is subject to several risks and uncertainties, many of which are beyond the Company’s control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Readers should not place undue reliance on forward- looking statements and forward-looking information and are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake any obligation to update such forward-looking information, whether because of new information, future events or otherwise, except as expressly required by applicable law.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche, President and CEO
RELEVIUM TECHNOLOGIES INC
Edward Ierfino
Investor Relations
Tel: (514) 562-1374
Email: eierfino@releviumcorp.com
Website: www.releviumtechnologies.com
- Published in News Home, Nutraceutical, Relevium Technologies
Relevium Files and Provides Comments on the Audited Consolidated Financial Statements
Momentum Public Relations
Press Release: October 31, 2017
MONTREAL, QUEBEC–(Marketwired – Oct. 31, 2017) – Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) (the “Company” or “Relevium”), a publicly traded corporation strategically focused on creating value through the acquisition and development of e-brands, online businesses and e-retail technologies in the Health and Wellness space, is pleased to announce the filing of the company’s Audited Financial Statements and MD&A for the fiscal year ended June 30, 2017 and 2016 on Sedar
News Release Highlights
- An active year focused on acquisitions and its impact on the income statement
- Impact of Bioganix and first quarter of the fiscal year ending June 30, 2018
- Major events impacting our Consolidated Statements of Financial Position
An active fiscal year focused on acquisitions
The fiscal year ended June 30, 2017 was a year dedicated to the identification, evaluation and negotiation with several acquisition targets. As the Audited Consolidated Financial Statements and MD&A reveal, the company’s expenses increased substantially for the fiscal year ended June 30, 2017, primarily the result of the non-cash impairment of the carrying value of the intellectual assets acquired as part of the company’s qualifying transaction in 2015, totaling $747,322. The additional increase in expenses of $567,677 in consulting fees were related primarily to acquisitions and related expenses. The combination of these major categories of expenses resulted in a net and comprehensive loss of $2,584,738 as compared to $1,557,719 in 2016.
Commenting on the results for the reporting period, Aurelio Useche, President and CEO stated: “It was a year dedicated to the execution of our first acquisition in our roll-up strategy. The process was challenging but effective”. Mr Useche added: “The impact from operations of newly acquired Bioganix will only take effect in the company’s Consolidated Financial Statements for the three-month period ended September 30, 2017 (Q1), which will be reported at the end of this month of November”
Major events impacting our Consolidated Statements of Financial Position
The Company reported significant changes to the Consolidated Statements of Financial Position, including an increase in total assets of $6,111,470 from $1,003,682 in 2016 to $7,115,152 in 2017. In parallel, the Company also reported significant changes in total liabilities of $4,343,533, from $447,031 in 2016 to $4,790,564 in 2017. Most of these changes transpired during the last quarter of the fiscal year ended June 30, 2017 and were primarily the result of an equity financing, a debenture financing and the execution of the definitive agreement and deposit to acquire BioGanix.
Commenting on these major events, Aurelio Useche, President and CEO stated: “From the execution of the binding agreement to the close of all three major events six months later, the company’s overall financial position has improved materially, positioning Relevium to continue to execute on the roll-up strategy”. Mr Useche added: “Relevium remains an entrepreneurial venture at heart and every single person in the team, from directors to the actual operators of the business, is guided by this principle in mind: We are Intense, Nimble and Lean”
The company looks forward to continuing to update shareholders.
About Relevium Technologies
Relevium is a TSXV listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking information within the meaning of applicable securities legislation, which reflects the Company’s current expectations regarding future events. Forward-looking information is based on several assumptions and is subject to several risks and uncertainties, many of which are beyond the Company’s control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Readers should not place undue reliance on forward- looking statements and forward-looking information and are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake any obligation to update such forward-looking information, whether because of new information, future events or otherwise, except as expressly required by applicable law.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche, President and CEO
RELEVIUM TECHNOLOGIES INC
Edward Ierfino
Manager, Investor Relations
Tel: (514) 562-1374
Email: eierfino@releviumcorp.com
Website: www.releviumtechnologies.com
- Published in News Home, Nutraceutical, Relevium Technologies
Relevium Provides Operational Progress Update and Appoints Senior Marketing Officer
Momentum Public Relations
Press Release: October 27, 2017
MONTREAL, QUEBEC–(Marketwired – Oct. 27, 2017) – Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) (the “Company” or “Relevium”), a publicly traded corporation strategically focused on creating value through the acquisition and development of e-brands, online businesses and e-retail technologies in the Health and Wellness space, is pleased to announce a brief operational update on progress and the appointment of a Senior Marketing Officer.
News Release Highlights
- RLV appoints Senior Marketing Officer
- BioGanix and General Progress Update
- Financial reporting
Appointment of Senior Marketing Officer
Relevium Technologies is pleased to announce it has appointed Abis Hussain as the company’s Senior Marketing Officer, overseeing the company’s overall marketing and branding activities for its current and future portfolio of e-brands.
Mr. Hussain has been actively engaged in the e-marketing space since 2007 and most recently was Director of Influencer Marketing, as well as, Director of Online Marketing at RhythmOne, a global leader in providing streamlined, transparent connections between advertisers and audiences through a combination of differentiated supply, innovative technology and data-driven insights.
While at RhythmOne, Mr. Hussain expanded client communities and focused in locating target audiences by building social media strategies in the United States and Europe. Mr. Hussain was instrumental in increasing brand awareness by 50{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} for various brands and companies including Subaru, Nestle and Kellogg’s and has worked with pro-athletes and influencers on behalf of clients.
Aurelio Useche, CEO of Relevium Technologies stated: ” Abis has a wealth of knowledge in the business of driving internet traffic from sources outside the Amazon ecosystem. Mr. Useche stated further: “The skillset that Abis brings to the table is extremely complimentary to the existing expertise of the operations team which is very Amazon-centric as it stands. Abis has already demonstrated himself as a strong leader and has kicked off great initiatives that will positively impact the performance of our business.”
Business Update
The acquisition of BioGanix has been a successful endeavor for Relevium and for its shareholders. Revenues have continued to grow by an average of 50{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} versus the same period in 2016 and our customer base continues to expand.
Since July, the Company has been focused on the optimization of the BioGanix brand through internal efforts and through new products and brand extensions. The BioGanix brand continues to expand with the soft launch of four new SKUs in November. The customer and revenues base are expected to continue to grow organically and as planned.
Shareholders can look forward to detailed information about the results from BioGanix for the three-month period ended September 30, 2017 on its first quarter filings due at the end of November 2017.
Shareholders should also be mindful that the financial impact of the operations of the BioGanix brand will not be part of the Audited Financials for the fiscal year ended June 30, 2017, which are due at the end of this month.
The Company’s CEO expects to hold a call for shareholders at the end of November in order to discuss first quarter performance and provide shareholders with an overview of progress and future strategy. Details will be provided in a subsequent press release.
About Relevium Technologies
Relevium is a TSXV listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking information within the meaning of applicable securities legislation, which reflects the Company’s current expectations regarding future events. Forward-looking information is based on several assumptions and is subject to several risks and uncertainties, many of which are beyond the Company’s control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Readers should not place undue reliance on forward- looking statements and forward-looking information and are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake any obligation to update such forward-looking information, whether because of new information, future events or otherwise, except as expressly required by applicable law.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche, President and CEO
RELEVIUM TECHNOLOGIES INC
Edward Ierfino
Manager, Investor Relations
Tel: (514) 562-1374
Email: eierfino@releviumcorp.com
Website: www.releviumtechnologies.com
- Published in News Home, Nutraceutical, Relevium Technologies, Technology
Relevium Signs LOI to Acquire Nutraceutical Brand
Momentum Public Relations
Press Release: October 25, 2017
MONTREAL, QUEBEC–(Marketwired – Oct. 25, 2017) – Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) (the “Company” or “Relevium”), a publicly traded corporation strategically focused on the acquisition and building of e-retail brands, products and technologies in the health and wellness market, is pleased to announce that it has signed a non-binding Letter Of Intent (the “LOI”) to acquire an American based nutraceutical brand that sells products direct to consumers primarily through the Amazon.com channel in the Vitamins and Dietary Supplements category. The transaction value is currently estimated at US$1.35 million, which shall be subject to adjustment based upon a multiple of earnings before income taxes.
Highlights
- Non-binding LOI for a Nutraceutical brand
- Targeted to close by November 30, 2017
- RLV Executes on guidance issued August 2, 2017
Subject to the positive outcome of a short due diligence period, the negotiation and execution of a mutually satisfactory definitive acquisition agreement and TSX Venture Exchange approval, management estimates that the transaction should close around November 30, 2017. Pursuant to regulatory guidelines, further financial details and related fees regarding the acquisition will be disclosed at the closing of the transaction. The Company does not anticipate the need for outside capital in order to close the transaction as the consideration is expected to consist solely by the issuance of additional equity of the Company which shall be subject to a vesting schedule and associated targets. The Company does not anticipate that a new control person will be created as a result of the proposed transaction.
Once closed, it is intended that the acquired assets will be transferred to Relevium and the operations will be integrated into the current operations being managed by the Company.
Aurelio Useche, President and CEO of Relevium Technologies stated: “We have been diligently looking at accretive assets to add to our portfolio since the acquisition of BioGanix and we are very pleased to execute another line item from our 2017 guidance laid out on August 2, 2017.”
Mr. Useche continued: “Once closed, this transaction will further demonstrate Management’s ability to execute on the M&A strategy and should contribute to top line revenue and EBITDA for Fiscal 2018. Operationally speaking we are ready to continue acquiring, integrating and optimizing brands. The current M&A pipeline remains very healthy and in line with previously stated numbers. We look forward to concluding more transactions on an aggressive schedule.”
About Relevium Technologies
Relevium is a TSXV listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking information within the meaning of applicable securities legislation, which reflects the Company’s current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company’s control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Readers should not place undue reliance on forward- looking statements and forward-looking information and are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche, President and CEO
RELEVIUM TECHNOLOGIES INC
Relevium Technologies Inc.
Edward Ierfino
Manager, Investor Relations
(514) 562-1374
eierfino@releviumcorp.com
www.releviumtechnologies.com
- Published in News Home, Nutraceutical, Relevium Technologies
Relevium Changes Auditors and Corporate Update
Momentum Public Relations
Press Release: October 20, 2017
MONTREAL, QUEBEC–(Marketwired – Oct. 20, 2017) – Relevium Technologies Inc. (TSX VENTURE:RLV) and (FRANKFURT:6BX) (the “Company” or “Relevium”) announced today that it has changed auditors and appointed Ernst & Young LLP, Chartered Professional Accountants, as the Company’s new auditor (the “Successor Auditor“), replacing Nexia Freedman LLP, Chartered Professional Accountants (the “Former Auditor“). At the request of the Company, the Former Auditor has resigned and the Successor Auditor has been appointed as of the effective date of October 11, 2017.
The Company’s Audit Committee and Board of Directors have approved the resignation of the Former Auditor and the appointment of the Successor Auditor. In accordance with National Instrument 51-102 – Continuous Disclosure Obligations, the notice of change of auditor, together with the letter from the Former Auditor and the letter from Successor Auditor have been reviewed by the Company’s Audit Committee and Board of Directors and are available under the Company’s profile at www.sedar.com. There were no reservations or modified opinions in the Former Auditor’s reports in connection with the financial statements of the Company for the Company’s most recent fiscal year and any subsequent period, and there are no “reportable events”, as defined in the National Instrument 51‐102 ‐ Continuous Disclosure Obligations, between the Company and the Former Auditor.
Aurelio Useche, CEO of Relevium Technologies stated “On behalf of our board of directors and the management team, we thank the team at Nexia Freedman for the services provided to the Company. We look forward to working with Ernst & Young, as the Company grows and executes its business plan.”
The Company also announces that, effective August 18, 2017, David A. Johnson has been appointed Corporate Secretary of the Company. Mr. Johnson is an attorney and a trademark agent and has served as an executive officer, director and audit committee member of various public companies listed on the TSX Venture Exchange and the Canadian Stock Exchange. In consideration for Mr. Johnson’s ongoing services as Corporate Secretary and in order to preserve its cash on hand, the Company has agreed, subject to TSX Venture Exchange approval, to issue common shares of the Company to Mr. Johnson at an amount of $2,500 per month whereby the price calculates the volume weighted average price, or VWAP, for the last five (5) trading days of the month.
Aurelio Useche, CEO of Relevium Technologies stated “We welcome the addition of Mr. Johnson to our team. His years of professional experience in public companies, corporate governance and legal knowledge will be a strategic asset to the Company.”
About Relevium Technologies
Relevium is a TSXV listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking information within the meaning of applicable securities legislation, which reflects the Company’s current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company’s control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Readers should not place undue reliance on forward-looking statements and forward-looking information and are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche, President and CEO
RELEVIUM TECHNOLOGIES INC
Relevium Technologies Inc.
Edward Ierfino
Manager, Investor Relations
(514) 562-1374
eierfino@releviumcorp.com
www.releviumtechnologies.com
- Published in News Home, Nutraceutical, Relevium Technologies, Technology
Relevium Technologies Reports Revenue of CAD$700,000 in the First 50 Days of Business
Momentum Public Relations
Press Release: October 16, 2017
October 16, 2017 / TheNewswire / MONTREAL, QUEBEC, Momentum PR client, Relevium Technologies., is listed on the TSX Venture Exchange under the symbol: RLV and in Germany on the FSE under the symbol: 6BX.
Momentum PR is pleased to have produced an informative and comprehensive report on Relevium Technologies, available on the Momentum PR website.
Relevium Business Model:
– Montreal-based Relevium Technologies has embarked on an aggressive acquisition plan to become a Canadian brand name in the booming e-commerce health and wellness sector; concentrating on the nutraceutical and cosmeceutical markets.
–Goldstein Research predicts US$300 Billion Nutraceutical Market By 2024
Creating new Brands
-Building new brands for fitness and pet nutraceuticals
BioGanix:
–Relevium has recently closed its acquisition of BioGanix, a profitable health and wellness supplements brand with a product line of 25 best-selling supplements.
-During the first 50 days BioGanix sales reached $CAD 700,000. BioGanix is operating under Relevium’s US subsidiary BGX E-Health.
AgileDSS:
–Relevium hired agileDSS as a data architect to start work on the company’s big data and AI Product Trend-Recognition Engine.
-The company believes that if it is successful, the Product Trend-Recognition Engine would allow it to launch the right products in the right market, long before any competitor.
HempCo:
-In May, Relevium signed an exclusive e-retail agreement with HempCo Food and Fiber, (TSXV:HEMP).
-HempCo sells hemp protein powder, hemp oil and hulled hemp seed nut, under its brand PlanetHemp on a B2B (business-to-business) basis.
-The agreement calls for the joint development of a complete line of hemp-based nutraceutical and nutritional products, for distribution through global e-commerce platforms including Amazon and Jet.com. Relevium will also develop B2C (business-to-consumer).
Research house MarketsandMarkets has predicted that the global wellness supplement market will hit US$249.4 Billion during 2020, up from US$183.1 Billion in 2015.
Relevium Technologies CEO Aurelio Useche describes the sectors like this: “Both nutraceuticals and cosmeceuticals come from the combination of nature and science. They are a combination of natural ingredients with some science behind them.”
The market is being driven by a variety of factors, ranging from increased knowledge about the benefits supplements can provide, to aging boomers wanting to live better longer. Another driver is the increasing belief that natural ingredients are better than synthetic compounds, with far fewer side effects.
Relevium is also in advanced discussions with other e-commerce companies and is targeting the execution of a second acquisition of either a nutraceutical or cosmeceutical company by the end of the year.
“I see the company becoming a portfolio of health and wellness brands that have become well-recognized in the marketplace. In terms of size, we aim for a company with C$500 Million in annual revenues and the ability to offer our investors dividends,” said CEO Aurelio Useche.
Relevium trades on the TSXV as RLV and on the FSE as 6BX. As of October 11, 2017 it closed at C$0.12 and has a 52-week high of C$0.22 and a low of C$0.045. The company has 66,971,466 shares outstanding and a market cap of C$7.9 million.
The Momentum PR informative and comprehensive report on Relevium Technologies is available on the Momentum PR website.
If you would like more information on Relevium; listed on the TSX Venture Exchange under the symbol RLV or would like to arrange an interview with management please contact:
Momentum PR
Juliette Benard, Director Media Relations
+1.450.332.6939
media@momentumpr.com
info@momentumpr.com
About Momentum PR
Momentum PR is a cutting-edge public and investor relations consulting agency representing companies within the Canadian investment community.
Since 2009, Momentum PR has been servicing small and mid-cap Canadian listed public companies, seeking to increase their exposure across North America. The focus at Momentum PR is on building and driving brand awareness. Momentum PR cultivates new audiences in the media and investment communities by proactively engaging interested parties on behalf of client companies through online and offline channels.
Read it on The Newswire
- Published in News Home, Nutraceutical, Relevium Technologies, Technology
Relevium, Salavenia to develop products for pets
Relevium Creates Alliance With Salavenia Nutrition and Biodevas Laboratoires to Develop an Exclusive Line of Phyto and Nutraceuticals for Pets
MONTREAL, QUEBEC–(Marketwired – Sept. 28, 2017) –Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) (the “Company” or “Relevium”) is pleased to announce the launch of a joint cooperation with Salvenia Nutrition and Biodevas Laboratoires to develop an exclusive brand and product line of nutraceuticals and phytoceuticals targeted to Pet Care owners on a direct to consumer basis. Product and market development initiatives are expected to begin in October of this year with the objective of a preliminary launch by Spring of 2018 as a wholly-owned subsidiary of Relevium.
Relevium has retained Salvenia Nutrition (“Salvenia”), a Montreal based pet and livestock nutrition company, to lead the market research and the product line formulation process, which will consist of nutraceutical and phytoceutical based products. In addition to their long-standing expertise, Salvenia Nutrition is also an exclusive North American distributor of Biodevas Laboratoires, a leading manufacturer of veterinary Phytoceutical products based in France. Such exclusivity will be extended to Relevium’s newly developed product line for e-commerce for an initial 18-month period from the first product launch date, which is expected by spring of 2018.
Salvenia Nutrition with the assistance of a local nutraceutical formulation lab will develop new products in conjunction with the existing products currently available from the Biodevas Laboratoires.
Further updates will be issued as they become available.
Aurelio Useche, CEO of Relevium Technologies stated, “Much like their owners, pets can also suffer from nutritional deficiencies related to poor dietary intake. Keeping pets healthy and stronger requires nutritional supplements, a market that is estimated to be north of 16 billion in North America alone. We look forward to leveraging the expertise of Salvenia and Biodevas Laboratoires to develop a high quality product line to fill a real need in this market.”
About Relevium Technologies
Relevium is a TSXV listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Business, Financial Technology, Life Sciences, Relevium Technologies